- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05506943
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Patricia Gonzalez
- Phone Number: 151 617-500-8099
- Email: CTX-009-002@compasstherapeutics.com
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85054
- Recruiting
- Mayo Clinic Arizona
-
Contact:
- Clinical Trials Referral Office
- Phone Number: 855-776-0015
-
Principal Investigator:
- Mitesh Borad, MD
-
Tucson, Arizona, United States, 85724-5024
- Recruiting
- University of Arizona
-
Contact:
- Prisca Zimmerman
- Email: priscaz@arizona.edu
-
Contact:
- Brianna Loughran
- Email: bloughran@arizona.edu
-
Principal Investigator:
- Rachna T Shroff, MD
-
-
California
-
Los Angeles, California, United States, 90033
- Recruiting
- University of Southern California Norris Comprehensive Cancer Center
-
Principal Investigator:
- Anthony El-Khoueiry, MD
-
Contact:
- Carryl Du Bois
- Email: Carryl.DuBois@med.usc.edu
-
Contact:
- Charlean Ketchens
- Email: ketchens_c@med.usc.edu
-
Palo Alto, California, United States, 94305
- Recruiting
- Stanford Medicine Cancer Center
-
Principal Investigator:
- Gregory Heestand, MD
-
Contact:
- Yasmeen Ahmed
- Email: yahmed@stanford.edu
-
San Francisco, California, United States, 94143-1770
- Recruiting
- University of California San Francisco
-
Principal Investigator:
- Katie Kelley, MD
-
Contact:
- Quincy Harris
- Email: Quincy.Harris@ucsf.edu
-
Contact:
- Maxine Hamilton
- Email: Maxine.Hamilton2@ucsf.edu
-
-
Colorado
-
Aurora, Colorado, United States, 80012
- Recruiting
- Rocky Mountain Cancer Centers, LLP
-
Contact:
- Jennifer Hege
- Email: Jennifer.Hege@USOncology.com
-
Principal Investigator:
- Sujatha Nallapareddy, MD
-
-
Florida
-
Gainesville, Florida, United States, 32611
- Recruiting
- University of Florida
-
Principal Investigator:
- Ilyas Sahin, MD
-
Contact:
- Allison Springer, MEd
- Email: sheehanallison@ufl.edu
-
Jacksonville, Florida, United States, 32224
- Recruiting
- Mayo Clinic Jacksonville
-
Contact:
- Clinical Trials Referral Office
- Phone Number: 855-776-0015
-
Principal Investigator:
- Umair Majeed, MD
-
Orlando, Florida, United States, 32804
- Recruiting
- AdventHealth Orlando
-
Principal Investigator:
- Mohamedtaki Tejani, MD
-
Contact:
- Anh Le
- Phone Number: 407-303-8274
- Email: anh.le@adventhealth.com
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- Recruiting
- University of Chicago
-
Contact:
-
Contact:
- Hang Chang
- Phone Number: 773-702-3482
- Email: hchang@bsd.uchicago.edu
-
Principal Investigator:
- Chih-Yi (Andy) Liao, MD
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern University
-
Principal Investigator:
- Aparna Kalyan, MD
-
Contact:
- Mohammed Abdulrahman Mohammed
- Email: mohammedabdulrahman.mohamm@northwestern.edu
-
Contact:
- Anastasia Papaioannou
- Phone Number: 630-938-2085
- Email: anastasia.papaioannou@nm.org
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Recruiting
- Ochsner Clinic Foundation
-
Contact:
- Elise Curry, CRC
- Phone Number: 504-842-8084
- Email: elisemarie.curry@ochsner.org
-
Contact:
- Nancy Perez, CRC
- Phone Number: 504-842-0179
- Email: nancy.perez@ochsner.org
-
Principal Investigator:
- Lingling Du, MD
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Recruiting
- Johns Hopkins University
-
Principal Investigator:
- Nilofer Azad, MD
-
Contact:
- GI Clinical Trials
- Email: GIClinicaltrials@jhmi.edu
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02141
- Recruiting
- Massachusetts General Hospital
-
Principal Investigator:
- Priyadarshini Pathak, MD
-
Contact:
- Ashley O'Meara
- Email: ALOMEARA@mgh.harvard.edu
-
Contact:
- Joanna Caufield, RN
- Email: jlcaufield@mgb.org
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic Rochester
-
Contact:
- Clinical Trials Referral Office
- Phone Number: 855-776-0015
-
Principal Investigator:
- Nguyen Tran, MD
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University School of Medicine, Siteman Cancer Center
-
Principal Investigator:
- Olivia Aranha, MD
-
Contact:
- David Timm
- Phone Number: 314-215-7337
- Email: Timmd@wustl.edu
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08854
- Recruiting
- Rutgers Cancer Institute
-
Principal Investigator:
- Howard Hochster, MD
-
Contact:
- Lead Clinical Research Coordinator
- Email: perez11@cinj.rutgers.edu
-
Contact:
- Back-Up Clinical Research Coordinator
- Email: uq5@cinj.rutgers.edu
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131
- Recruiting
- The University of New Mexico
-
Contact:
- Email: glritcher@salud.unm.edu
-
Contact:
- Email: lmancha@salud.unm.edu
-
Principal Investigator:
- Ursa Brown-Glaberman, MD
-
Las Cruces, New Mexico, United States, 88011
- Recruiting
- Memorial Medical Center
-
Contact:
- Email: glritcher@salud.unm.edu
-
Contact:
- Email: lmancha@salud.unm.edu
-
Principal Investigator:
- Ursa Brown-Glaberman, MD
-
-
New York
-
Bronx, New York, United States, 10461
- Recruiting
- Montefiore Medical Center
-
Contact:
- Chika Ekweghariri
- Email: cekweghari@montefiore.org
-
Principal Investigator:
- Fernand Bteich, MD
-
Buffalo, New York, United States, 14263
- Recruiting
- Roswell Park
-
Principal Investigator:
- Renuka Iyer, MD
-
Contact:
- Mary Lynne Tarquini
- Email: marylynne.tarquini@roswellpark.org
-
Contact:
- Sarah Chatley
- Email: Sarah.Chatley@RoswellPark.org
-
New York, New York, United States, 10032
- Recruiting
- Columbia University
-
Contact:
- Nurse Navigators
- Phone Number: 212-342-5162
- Email: cancerclinicaltrials@cumc.columbia.edu
-
Principal Investigator:
- Ruth White, MD
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Recruiting
- Gabrail Cancer Center
-
Principal Investigator:
- Nashat Y Gabrail, MD
-
Contact:
- Nashat Gabrail
- Email: research@gabrailcancercenter.com
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic
-
Principal Investigator:
- Suneel Kamath, MD
-
Contact:
- Cancer Center Hotline
- Phone Number: 866-223-8100
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37920
- Recruiting
- University of Tennessee medical Center
-
Principal Investigator:
- Saikrishna Gadde, MD
-
Contact:
- Dani Joyner, BSN, RN, OCN
- Phone Number: 865-305-3565
- Email: jdjoyner@utmck.edu
-
Nashville, Tennessee, United States, 37203
- Recruiting
- SCRI Oncology Partners
-
Contact:
- askSARAH
- Phone Number: 844-482-4812
-
Principal Investigator:
- Meredith P Pelster, MD
-
-
Texas
-
Austin, Texas, United States, 78705
- Recruiting
- Texas Oncology - Austin
-
Contact:
- Jennifer Rowan
- Email: jennifer.rowan@usoncology.com
-
Principal Investigator:
- Vivian Cline, MD
-
Dallas, Texas, United States, 75246
- Recruiting
- Texas Oncology - Baylor Charles A. Sammons Cancer Center
-
Contact:
- Christine Terraciano
- Email: Christine.Terraciano@usoncology.com
-
Principal Investigator:
- Andrew Scott Paulson, MD
-
Denison, Texas, United States, 75020
- Recruiting
- Texas Oncology - Dension
-
Contact:
- Jayne Mettetal
- Email: jayne.mettetal@usoncology.com
-
Principal Investigator:
- Amir Faridi, MD
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas MD Anderson Cancer Center
-
Contact:
-
Principal Investigator:
- Zishuo Ian Hu, MD
-
San Antonio, Texas, United States, 78217
- Recruiting
- Texas Oncology - San Antonio
-
Contact:
- Shannon Syring
- Email: Shannon.Syring@usoncology.com
-
Principal Investigator:
- Nathan Shumway, DO
-
Tyler, Texas, United States, 75702
- Recruiting
- Texas Oncology - Northeast Texas
-
Contact:
- Shelly K Maxfield
- Email: shelly.maxfield@usoncology.com
-
Principal Investigator:
- Donald A Richards, MD, PhD
-
-
Washington
-
Seattle, Washington, United States, 98101
- Recruiting
- Virginia Mason Franciscan Health
-
Principal Investigator:
- Bruce Lin
-
Contact:
- Cancer Clinical Research Unit Research hotline
- Phone Number: 206-287-6270
-
Contact:
- Bruce Lin, MD
- Phone Number: 206-223-6193
- Email: bruce.lin@virginiamason.org
-
Vancouver, Washington, United States, 98684
- Recruiting
- Northwest Cancer Specialists, P.C.
-
Principal Investigator:
- David P Cosgrove, MD
-
Contact:
- Jennifer Thompson
- Email: Jennifer.Thompson@usoncology.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
INCLUSION CRITERIA
- 18 years of age or older
- Histologically or cytologically confirmed unresectable advanced, metastatic, or recurrent biliary tract cancers (including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma)
Patients must have radiologically documented progression after a prior gemcitabine and platinum containing chemotherapy regimen as first line therapy for locally advanced unresectable or metastatic disease.
- Patients who received perioperative treatment (adjuvant and neoadjuvant) may be eligible, as determined by the Sponsor Medical Monitor.
- Patients whose first line regimen was modified due to toxicity before disease progression, may be eligible, as determined by the Sponsor Medical Monitor.
- At least one lesion measurable as defined by RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
- Predicted life expectancy of at least 12 weeks
No evidence of ongoing infection and adequate biliary excretion or patients whose adequate biliary excretion can be confirmed with the following procedures:
- Patients who underwent endoscopic retrograde biliary drainage (ERBD) at least 1 week before the investigational drug treatment
- Patients with endobiliary stents are eligible, provided there is no evidence of obstruction
- Patients free of any signs of active or suspected uncontrolled infection after a drainage procedure
- Patients free of any risk of hemorrhage and with incision completely healed
Adequate bone marrow, hepatic, and renal function within 14 days of randomization as described below. (Patient must be free of G-CSF treatment and blood transfusion within 14 days prior to the lab test):
- Absolute neutrophil count (ANC) ≥ 1,500/mm3
- Hemoglobin ≥ 9.0 g/dL
- Platelet count ≥ 100,000/mm3
- Total bilirubin ≤ 1.5 X ULN
- AST/ALT ≤ 3.0 X ULN (≤5 X ULN in case of hepatic metastasis)
- Estimated creatinine clearance ≥ 30 mL/min based on Cockcroft-Gault
- Urine protein ≤ 1+ by Dipstick (Only when urinalysis shows a protein dipstick result of > 1 positive (+), the total protein volume (<1.0 g/24hr) can be confirmed with a 24-hour urine test.)
- Serum amylase and lipase level ≤ 3X ULN
- Serum Albumin ≥ 3.0 g/dL
- Female patients who are women of childbearing potential (WCBP) must have a negative pregnancy test (serum-hCG or urine-hCG performed at the Investigator's discretion) within 14 days of randomization
- Female patients must be surgically sterile (or have a monogamous partner who is surgically sterile) or be at least 2 years postmenopausal or commit to use 2 acceptable forms of birth control (defined as the use of an intrauterine device (IUD), a barrier method with spermicide, condoms, or any form of hormonal contraceptives) or abstinence for the duration of the study and for 6 months following the last dose of study treatment. Male patients must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study and for 6 months following the last dose of study treatment.
- Signed and dated Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved Informed Consent Form (ICF) before any protocol-directed screening procedures are performed
EXCLUSION CRITERIA
- Patients who are eligible to be treated with a molecularly targeted therapy on a labelled regimen after receiving first-line chemotherapy. Patients who received a molecularly targeted therapy as part of their first line treatment may be eligible, as determined by the Sponsor Medical Monitor.
From the time point of screening,
- Less than 4 weeks have elapsed since patients had a surgery or major procedure
- Less than 2 weeks have elapsed from the last treatment date since patients had any radiation therapy
- Patients with percutaneous transhepatic biliary drains (PTBD)
Prior to the initial treatment of study drug,
- Less than 2 weeks have elapsed since patients had chemotherapy or hormone therapy
- Less than 2 weeks have elapsed since patients had anticancer immunotherapy or investigational drug treatment
- Less than 4 weeks since cryotherapy, radiofrequency ablation, anhydrous alcohol therapy, or photodynamic therapy, including TACE and TARE
A history of the following cardiovascular diseases (please, consult the Sponsor Medical Monitor for a case by case evaluation):
- Congestive heart failure (CHF) that corresponds to Class II or a higher class under New York Heart Association (NYHA) classification, or less than 50% of left ventricular ejection fraction (LVEF)
- Uncontrolled hypertension (SBP/DBP >140/90 mmHg) (e.g., patient with SBP/DBP >140/90 mmHg despite the best care including optimizing the anti-hypertensive medication regimen)
- Patients with any history of hypertensive crisis or pre-existing hypertensive encephalopathy
- Pulmonary hypertension
- Myocardial infarction
- Uncontrolled arrhythmia
- Unstable angina
- Patients with any significant vascular diseases (e.g., aortic aneurysm requiring surgery or recent peripheral artery thrombosis) within 6 months prior to the initial treatment of the investigational product
- History of hypersensitivity reactions to any components of the investigational product or other drugs of the same class (humanized/human monoclonal antibody drugs) or paclitaxel
- Patients with contraindications to paclitaxel therapy
- Patients with persistent, clinically significant toxicities (excluding hair loss) from previous anticancer treatment that corresponds to Grade 2 or a higher grade under NCI-CTCAE v5.0
- Symptomatic or uncontrolled central nervous system (CNS) metastasis (However, patients with asymptomatic CNS metastasis that have been treated with either surgery or radiation can participate provided that systemic corticosteroid treatment was discontinued at least 4 weeks prior to screening and that the patient is radiologically and neurologically stable or improving)
A history of the following hemorrhage-related or gastroenterological disease:
- Active hemorrhage, hemorrhagic diathesis, coagulopathy or tumor in great arteries
- History of clinically significant gastroenterological disease, such as peptic ulcer, GI bleeding, GI or non-GI fistula, perforation, abdominal abscess, clinical symptoms, and signs of GI obstruction, need for parenteral hydration or nutrition, or inflammatory bowel disease (IBD)
Current or recent (within 10 days prior to study treatment) use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purpose will be excluded.
a. Prophylactic (i.e., for the patency of venous access devices) use of low molecular weight heparin (i.e., enoxaparin 40 mg/day) is allowed if patient has INR < 2 or aPTT </=2x ULN within 14 days of study treatment
- Patients with current or recent (within 10 days of study treatment) use of aspirin (>81 mg/day), or other nonsteroidal anti-inflammatory drugs (NSAIDs), or other antiplatelets (i.e., dipyramidole, ticlopidine, clopidogrel, and cilostazol) will be excluded.
- Severe infection requiring ongoing systemic antibiotics, antivirus drugs, etc., or other uncontrolled acute active infectious diseases
- Patients with evidence of active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Patients with positive HBsAg and/or detectable HBV DNA are eligible only if adequately controlled on antiviral therapy according to institutional standards and liver function eligibility criteria are also met. HCV patients showing sustained viral response or patients with immunity to HBV infection may enroll.
Patients with other severe diseases or uncontrolled illnesses that warrant the exclusion from the study (permitted only if medically controlled) including but not limited to:
- Pre-existing hemoptysis (≥ 1/2 teaspoon of bright red blood per episode) within 28 days prior to screening
- Major, unhealed injury, active ulcer, or untreated fracture
- Pre-existing conditions of cerebrovascular incident (ischemic or hemorrhagic stroke), transient ischemic attack or subarachnoid hemorrhage within 6 months prior to screening.
- Moderate to severe ascites and/or pleural effusion. However, enrollment is permitted for patients with ascitic fluid as long as paracentesis is not required to improve the condition.
- Interstitial lung disease or pulmonary fibrosis
- Patients expected to require anticancer treatment other than the investigational product during the clinical study
- Pregnant or lactating patients, or patients planning to become pregnant during the clinical study
- A history of primary malignancy other than BTC will be excluded, except for malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate >90%). Prior malignancy history will be evaluated on a case-by-case basis by the Sponsor Medical Monitor.
- Clinically significant abnormal ECG findings or history determined as clinically significant by the Investigator
- QT interval (Fridericia's formula) (QTcF) interval > 450msec at the time of screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CTX-009 plus Paclitaxel
|
IV infusion on day 1 and 14 of every 28 day cycle
IV infusion on day 1, 8, and 15 of every 28 day cycle
|
Active Comparator: Paclitaxel
Patients randomized to receive paclitaxel only have the option to crossover to the CTX-009 plus paclitaxel arm after documented disease progression per RECIST v1.1.
|
IV infusion on day 1, 8, and 15 of every 28 day cycle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best Overall Response
Time Frame: From randomization to treatment discontinuation for any reason, average 6 months
|
Percentage of patients whose Best Overall Response (BOR) is assessed as Complete Response (CR) or Partial Response (PR) as assessed by RECIST 1.1
|
From randomization to treatment discontinuation for any reason, average 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exposure Response by Pharmacokinetic (PK) Sampling
Time Frame: From C1D1 to treatment discontinuation for any reason, average of 6 months
|
Serum concentrations of CTX-009 at specified timepoints
|
From C1D1 to treatment discontinuation for any reason, average of 6 months
|
Disease Control Rate
Time Frame: From randomization to treatment discontinuation for any reason, average 6 months
|
Percentage of patients whose BOR is assessed as CR, PR, or Stable Disease (SD)
|
From randomization to treatment discontinuation for any reason, average 6 months
|
Duration of Response
Time Frame: From first confirmed CR or PR to confirmed PD, average 6 months
|
The time between the date of the radiological evaluation that first confirmed CR or PR and the date of the radiation evaluation that first confirmed Progressive Disease (PD)
|
From first confirmed CR or PR to confirmed PD, average 6 months
|
Progression Free Survival
Time Frame: From randomization to first documented objective PD or death if PD does not occur, average 6 months
|
Time from randomization until the date of objective PD (as assessed by RECIST 1.1) or the date of death (by any cause in the absence of disease progression)
|
From randomization to first documented objective PD or death if PD does not occur, average 6 months
|
Overall Survival
Time Frame: From randomization to death from any cause, average 12 months
|
Time from randomization until the date of death by any cause.
Patients who are still alive at the time of the analysis, or who have become lost to follow-up or withdrawn consent will be censored at their last date known to be alive
|
From randomization to death from any cause, average 12 months
|
Safety Profile of CTX-009 in Combination with Paclitaxel
Time Frame: From randomization to 60 days after the last dose of study treatment, average 7 months
|
Incidence of Treatment Emergent Adverse Events (TEAEs) and changes in clinical abnormalities for all randomized patients who received at least one dose of study treatment (either CTX-009 or paclitaxel)
|
From randomization to 60 days after the last dose of study treatment, average 7 months
|
Patient Reported Quality of Life
Time Frame: From randomization to treatment discontinuation for any reason, average 6 months
|
Assessed approximately every 2 months from patient reported data using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire (QLQ)-C30 and BIL21
|
From randomization to treatment discontinuation for any reason, average 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Minori Rosales, MD, PHD, Compass Therapeutics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Gallbladder Diseases
- Biliary Tract Diseases
- Cholangiocarcinoma
- Biliary Tract Neoplasms
- Gallbladder Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
Other Study ID Numbers
- CTX-009-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cholangiocarcinoma
-
Mayo ClinicRecruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Cholangiocarcinoma | Refractory Cholangiocarcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Advanced CholangiocarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic Cholangiocarcinoma | Oligometastatic Intrahepatic CholangiocarcinomaUnited States
-
RedHill Biopharma LimitedCompletedCholangiocarcinoma | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Perihilar | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, IntrahepaticUnited States
-
RedHill Biopharma LimitedAvailableCholangiocarcinoma | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Perihilar | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic
-
University of Kansas Medical CenterNational Cancer Institute (NCI)RecruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Cholangiocarcinoma | Locally Advanced Cholangiocarcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Recurrent CholangiocarcinomaUnited States
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH); CelgeneActive, not recruitingResectable Cholangiocarcinoma | Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8United States
-
Emory UniversityNational Cancer Institute (NCI)WithdrawnStage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Resectable Intrahepatic Cholangiocarcinoma | Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8 | Stage I Intrahepatic Cholangiocarcinoma AJCC v8United States
-
AIO-Studien-gGmbHServierCompletedCholangiocarcinoma Non-resectable | Cholangiocarcinoma of the Gallbladder | Cholangiocarcinoma Metastatic | Cholangiocarcinoma AdvancedGermany
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)TerminatedMetastatic Cholangiocarcinoma | Unresectable Cholangiocarcinoma | Advanced CholangiocarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic CholangiocarcinomaUnited States
Clinical Trials on CTX-009
-
Compass TherapeuticsActive, not recruitingMetastatic Colorectal Cancer | Rectal Cancer | Colon CancerUnited States
-
Alexza Pharmaceuticals, Inc.Completed
-
Alexza Pharmaceuticals, Inc.CompletedParkinson's DiseaseNetherlands
-
Suzhou Yabao Pharmaceutical R&D Co., Ltd.Completed
-
Suzhou Yabao Pharmaceutical R&D Co., Ltd.Not yet recruiting
-
Eisai Co., Ltd.Completed
-
Everfront Biotech Co., Ltd.Not yet recruitingPancreatic Cancer
-
Suzhou Yabao Pharmaceutical R&D Co., Ltd.Completed
-
Argos TherapeuticsCompletedInflammation | Systemic Lupus Erythematosus (SLE)United States
-
HanAll BioPharma Co., Ltd.CompletedMild to Moderate Atopic DermatitisUnited States